Tirzepatide is studied as a dual incretin receptor agonist associated with both glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) signaling. This dual-pathway profile is what separates Tirzepatide from single-pathway GLP-1 research compounds. In metabolic research, GIP and GLP-1 pathways are commonly explored for their roles in glucose response, insulin signaling, appetite regulation, satiety signaling, gastric-emptying patterns, and energy-balance biology.
The scientific interest around Tirzepatide comes from the way these two incretin pathways may work together in metabolic models. GLP-1 signaling is commonly associated with satiety and glucose-dependent insulin response, while GIP signaling is studied for its role in incretin activity, lipid handling, and metabolic regulation.



